these patients initially present with distant metastases, resulting in 5-year survival rates in this subgroup <12%. 2 The liver is the most common and frequently dominant site of metastatic disease, occurring in 20 to 30% of patients at diagnosis with a prevalence up to 60% during the course of disease. 3 Although surgical resection of the primary tumor and liver metastases is the most favorable treatment option (achieving 5-year survival rates of 37 to 58%), only 10 to 25% of patients with hepatic metastases from CRC (hmCRC) are candidates for hepatic resection at initial presentation. 4, 5 In addition, of these, most patients develop recurrent disease after hepatic metastatectomy. For unresectable hmCRC patients, systemic chemotherapy remains the standard first-line therapy. Despite significant gains in therapeutic efficacy achieved in the past decade with modern systemic regimens that combine fluoropyrimidines and leucovorin with oxaliplatin (FOLFOX), irinotecan (FOLFIRI), and/or molecularly targeted biological agents such as bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA), cetuximab (Erbitux; Bristol-Meyers Squibb Co., Princeton, NJ), panitumumab (Vectibix; Amgen, Inc., Thousand Oaks, CA), and regorafenib (Stivarga; Bayer HealthCare Pharmaceuticals, Wayne, NJ), 6,7 most patients eventually develop progressive disease. There therefore remains a need for liver-directed locoregional therapies for patients with unresectable liverdominant or liver-only hmCRC, especially those who fail frontline systemic treatment regimens. Hepatic intra-arterial therapies for hmCRC are intuitively attractive because the blood supply to liver metastases is almost exclusively via the hepatic arteries, whereas vascularization of normal liver parenchyma is 70% portal and 30% arterial. 8 Catheter-based hepatic intra-arterial therapies thus preferentially deliver therapeutic agents to metastatic foci while minimizing systemic exposure and treatment-associated toxicities. Contemporary intra-arterial treatment options for hmCRC include radioembolization (RE) with microspheres labeled with the β emitter yttrium-90 ( 90 Y);
(conventional TACE) or drug-eluting beads loaded with irinotecan (DEBIRI-TACE); hepatic arterial infusion (HAI) of chemotherapy; and percutaneous hepatic perfusion (PHP, also termed chemosaturation) using an organ isolation perfusion system with melphalan.
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Treatment Triage and Rationale
Relative to other hepatic intra-arterial therapeutic options, there is a more robust and mature body of evidence supporting the use of 90 Y RE to treat unresectable hmCRC patients.
The data have consistently demonstrated clinical benefits and a low toxicity profile with this treatment regimen, with fatigue the most common adverse effect. Moreover, among metastatic processes, unresectable hmCRC has been the most extensively studied indication for RE. This collective clinical experience, resulting from phase 1 through 3 clinical trials that include prospectively randomized studies, is comprehensively summarized in recent reviews.
10-14
Although several studies have shown early evidence that RE combined with systemic chemotherapy regimens potentiates treatment response compared with chemotherapy alone, [15] [16] [17] [18] [19] [20] further investigation is required to better define the role of RE as first-or second-line therapy in the treatment paradigm for hmCRC (►Fig. 1). 13 The currently available data, Y resin microspheres was 35.5%, with stable disease in 55%. 22 Median overall survival in this study was 10.5 months among responders and 4.5 months in nonresponders. These results compare favorably with systemic salvage studies, where median overall survival rates range from 3 to 7 months.
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Because most unresectable hmCRC patients referred to our practice for hepatic intra-arterial therapy present in the salvage therapy setting, 
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Thus hmCRC patients with bilobar disease, which are the majority in the salvage setting, need to undergo four procedures. Furthermore, the DEBIRI toxicity data suggest a more severe postembolization syndrome relative to RE, with grade 2 to 3 abdominal pain observed in up to 30% of treatment sessions.
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Conventional TACE is another option for the treatment of unresectable hmCRC. [36] [37] [38] [39] [40] There have been no studies directly comparing DEBIRI-TACE and conventional TACE; thus the decision to provide one over the other is often a matter of institutional preference. We currently prefer DEBIRI-TACE because of the encouraging results of recent clinical trials, the accepted role of irinotecan in frontline systemic regimens for metastatic CRC, and the paucity of compelling data favoring conventional TACE despite several decades of clinical experience. HAI requires implantation of a pump and an attached catheter placed through the gastroduodenal artery (GDA) and tip positioned at the GDA-hepatic artery junction for repeated intra-arterial delivery of various chemotherapy agents, most frequently floxuridine (FUdR). 49 2, bilirubin <2.0 mg/dL, and the absence of uncorrectable coagulopathy, renal function, or allergy issues that would preclude arterial catheterization or iodinated contrast angiography. We recommend RE only for patients in whom the hepatic disease is the most life threatening, and thus we do not perform RE on patients with brain metastases, extensive peritoneal metastases, debilitating lung or bone metastases, and so on. Furthermore, patients with a compromised ampulla of Vater, whether due to previous biliary surgery or biliary stent placement, are at high risk for infectious complications and should undergo antibiotic prophylaxis prior to and following this treatment. 50 Patients with biliary obstruction may undergo endoscopic or percutaneous drainage and Follow-up imaging studies 3 and 6 months after whole-liver RE treatment showed complete response of the metastases, which was sustained 1 year later while the patient was receiving systemic chemotherapy. be reevaluated for candidacy after normalization of biliary physiology. Salvage hmCRC patients tend to present with bilobar disease without underlying cirrhosis, and serum bilirubin is usually normal. However, in patients without biliary obstruction, liver function may be compromised due to extensive intrahepatic tumor burden or iatrogenic hepatic insults. Salvage patients typically have undergone numerous rounds of systemic chemotherapy before presenting for locoregional intra-arterial therapy, so it is imperative to obtain a thorough treatment history. Prior or ongoing systemic chemotherapy regimens with or without targeted biological agents, external-beam radiation therapy, hepatic surgery or ablation, or other intra-arterial therapies may have an impact on RE treatment planning, safety, and efficacy. Due to concern for potential increased risk of vascular injury and attenuated arteries that may lead to early reflux and nontarget embolization, bevacizumab is held for 4 to 6 weeks before the RE process. Radiosensitizing chemotherapies are typically held for at least 2 weeks to avoid superimposition of toxicities, but this practice may change as new data on combination therapies become available.
Preparatory Angiography and Technetium 99m-Macroaggregated Albumin Scintigraphy
The RE process is divided into two outpatient sessions performed up to 2 weeks apart. The overall goals of the first preparatory session are twofold: to skeletonize the hepatic arterial vasculature to ensure targeted delivery of 90 Y microspheres to tumor-bearing liver but not to the gastrointestinal tract, where inadvertent nontarget deposition can result in ulceration, 51 and then to quantify hepatopulmonary shunting by technetium 99m ( 99m Tc)-labeled macroaggregated albumin (MAA) scintigraphy. Meticulous angiography is performed to characterize the hepatic arterial supply, assess flow dynamics, identify hepaticoenteric arterial communications, and recognize tumor-supplying collateral vessels parasitized from extrahepatic arteries (EHAs). Endovascular isolation or skeletonization of the hepatic arterial vasculature is then performed by aggressive prophylactic embolization of visualized hepaticoenteric anastomoses to prevent nontarget gastrointestinal delivery. Parasitized EHAs and select variant hepatic arteries can be occluded to restore and consolidate intrahepatic hepatic artery inflow (►Fig. 2).
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The
53 After a parasitized EHA is confirmed by selective arteriography, it may be embolized to stasis using large particles with or without blockade of the parent EHA with coils. The purpose of this is not to induce tumor ischemia, but to restore intrahepatic arterial supply to territories previously perfused by the parasitized EHA through preexisting intrahepatic channels to allow for hepatic artery delivery of 90 Y microspheres to these regions.
Digital subtraction angiography (DSA) is performed with a 5F catheter positioned in the common hepatic artery to carefully identify vessels that may supply extrahepatic parenchyma (►Fig. 3). We routinely coil embolize the right gastric artery (RGA) and the GDA, unless planned selective administration of 90 Y microspheres is far distal to these vessels. Hepatic arteriography is often performed in at least two projections to better visualize the origin of the RGA, which most commonly arises from the proximal left or proper hepatic artery. Cannulation of the RGA can be challenging, requiring use of a preshaped microcatheter, formation of a Waltman loop, or retrograde catheterization via the left gastric artery. 54 For both the RGA and GDA, we aim to embolize the vessel completely to its origin because small Angiographic images of the left hepatic artery should be carefully reviewed for the presence of accessory left gastric, accessory phrenic, and inferior esophageal arteries. These should be coil embolized if identified. Prophylactic embolization of the cystic artery is controversial. Doing so does not appear to decrease the incidence of surgical cholecystitis ($1%); thus we only embolize the cystic artery if a bowelsupplying marginal or supraduodenal branch is identified originating from the cystic artery. For patients with replaced or accessory hepatic arteries, each variant hepatic artery is evaluated angiographically to characterize the hepatic territory supplied. In situations where the planned treatment territory is supplied by both a variant and nonvariant hepatic artery, the less dominant supplying vessel may be coil embolized to consolidate hepatic arterial inflow and thus simplify 90 Y microsphere administration. 52 Inflow consolidation can also improve safety by avoiding microsphere infusion into variant hepatic arteries that originate in close proximity to enteric branches, where reflux would result in gastrointestinal complications.
To determine the completeness of hepatic artery skeletonization and to evaluate where 90 Y microspheres will distribute in the liver, a microcatheter is positioned in the anticipated microsphere implantation site(s) to perform contrast-enhanced cone-beam C-arm CT (CACT) using an imaging protocol previously described. 55 If treatment of the whole liver is planned in a patient with standard hepatic arterial anatomy, contrast is administered via the proper hepatic artery. For planned lobar RE, contrast is injected through the respective lobar hepatic artery. CACT images are carefully scrutinized for possible extrahepatic parenchymal enhancement and areas of nonenhancement in the desired intrahepatic treatment territory. The former indicates the presence of unrecognized hepaticoenteric communications, whereas the latter signifies competitive intrahepatic perfusion by undetected accessory hepatic arteries or parasitized EHAs. We have found that CACT provides valuable arterial perfusion information not detectable by DSA or 99m Tc-MAA scintigraphy, and we frequently use this technology throughout the preparatory angiography session as a problemsolving tool to interrogate vessels in which it is unclear what tissue is being perfused.
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Once prophylactic embolization is satisfactorily completed, 1 mCi of 99m Tc-MAA is administered intra-arterially through a catheter positioned at the planned microsphere implantation site(s), as previously described for completion contrast-enhanced CACT. Patients then undergo planar scintigraphy to calculate lung shunt fraction (LSF) and singlephoton emission CT (SPECT) imaging to provide a second lower resolution means to evaluate for possible extrahepatic deposition and predict intrahepatic microsphere distribution. Unique to our practice, sulfur colloid (SC) imaging is also performed. Without moving the patient, 5 mCi of 99m Tc-SC is administered intravenously, and SPECT is repeated. 56 The 99m Tc-MAA and 99m Tc-SC SPECT data sets are fused and analyzed to better characterize predicted radiation dose distribution between normal liver and tumor.
Dosimetry
For resin 90 Y microspheres, the standard body surface area (BSA) method is used to calculate dose. Activity is determined using the following formulas: Activity in GBq ¼ (BSA À 0. . Percent tumor involvement is estimated according to preprocedure cross-sectional imaging and preparatory angiography and CACT images. Although the BSA method is recommended by consensus and by the manufacturing company, 57 it has recognized limitations.
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Improving and customizing dose calculation is the subject of ongoing investigations. Per manufacturer instructions, to minimize the risk of radiation pneumonitis, dose reduction should be considered when LSF is between 10% and 20%; RE should not be performed when LSF is >20%. 46 However, we prefer to calculate the expected pulmonary absorbed dose and make adjustments only if the exposure to the lungs is >30 Gy per treatment or 50 Gy cumulatively. 59 Fortunately, elevated LSF is rare in hmCRC patients. We also incorporate further dose adjustments or potentially fractionate treatment in hmCRC patients who are candidates for RE but are at higher risk for adverse events. Such situations may include an ECOG PS of 2, total bilirubin level of 1.5 to 2 mg/dL, advanced age, multiple lines of prior hepatotoxic systemic chemotherapy, previous resections or ablations, and history of external-beam radiation therapy that overlapped the hepatic region. For patients with bilobar disease, whole liver treatment may be performed in a single session or in two sequential lobar treatments at different sessions separated by 4 to 6 weeks. Whole liver single session treatment is preferred in part to prevent interval accelerated growth of contralateral untreated tumors and also to avoid potential medical insurance difficulties. To mitigate the risk for gastrointestinal complications, when feasible, single-session whole liver treatments are performed with sequential administrations via lobar arteries rather than delivery via the common or proper hepatic artery. For each infusion site, a separate microsphere dose is drawn and delivered.
Before microsphere delivery, a corticosteroid (dexamethasone 8 to 12 mg), a proton pump inhibitor (pantoprazole 40 mg), and an antiemetic (ondansetron 8 mg) are administered intravenously. Readers are referred to the package insert for detailed instructions on how to set up and use the device-specific administration apparatus. 33, 34 In the preoperative area, patients are provided the same prophylactic drugs as with RE, including antiemetics, dexamethasone, and a proton pump inhibitor. In addition, a patient-controlled analgesia (PCA) pump is prepared for postprocedure use. After the hepatic arterial anatomy is evaluated angiographically, a microcatheter is positioned at the desired location for selective bead delivery. The supernatant containing free irinotecan is removed, and the loaded beads are suspended in $20 mL of nonionic contrast. Before administration of the beads, 2 to 4 mL of 1% preservative-free lidocaine may be slowly injected intra-arterially to diminish potential TACErelated pain. 66 The beads are then slowly delivered under fluoroscopic imaging to monitor for reflux. Postprocedure, patients are admitted overnight with the PCA pump and antiemetic medications as needed for management of postembolization syndrome, and they are typically discharged the next day. After discharge, patients are prescribed a 30-day course of a proton pump inhibitor and oral analgesic and antiemetic agents as needed.
Conclusions
Based on the current literature on intra-arterial therapies for unresectable hmCRC, appropriate candidates are treated with 90 Y RE using resin microspheres, usually in the salvage setting. Given the less mature data for DEBIRI-TACE, this treatment modality is currently reserved for patients who have contraindications to RE or present with residual or recurrent metastatic disease after RE. The role of intraarterial therapies will continue to evolve and further integrate into the treatment algorithm for hmCRC as level I data become available. There is considerable optimism for the use of 90 Y RE earlier in the disease process and with concomitant radiosensitizing chemotherapy regimens as frontline treatment for hmCRC. [15] [16] [17] [18] [19] [20] Several prospective clinical trials combining RE with chemotherapy regimens and/or biological agents are currently underway, and they will undoubtedly affect the way interventional radiologists care for patients with metastatic CRC.
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